Overview

A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia

Status:
Enrolling by invitation

Trial end date:
2026-04-30

Target enrollment:

Participant gender:

Summary

This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of infigratinib in children and adolescents with achondroplasia (ACH) who have completed at least 26 weeks of participation in the QED-sponsored study PROPEL (QBGJ398-001).

Phase:

Phase 3

Details

Lead Sponsor:

QED Therapeutics, Inc.

Treatments:

Infigratinib